Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

Report from Canada’s Drug Agency says Wegovy cuts risk of heart attack, stroke or cardiovascular death by 20 per cent ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...

Taking prescription drugs on holiday without declaring them to your insurance provider can cause problems if you need to make a claim. | ITV National News ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide ... 25% body weight loss compared to ...

The results are a boost to Novo Nordisk after another weight-loss therapy ... with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.